Regor Therapeutics Group

We aspire to be a world class innovative drug discovery company from China.

Add To Watchlist
General Information
Company Name
Regor Therapeutics Group
Founded Year
2018
Location (Offices)
Shanghai, China +2
Founders / Decision Makers
Wenge Zhong - Founder ,Chief Technology Officer & Executive VP of Research, Chemistry Xiayang Qiu - Chief Executive Officer & Founder Min Zhong - Chief Operating Officer & Co-Founder
Number of Employees
29
Industries
Biotechnology, Pharmaceutical
Funding Stage
Series Unknown
Social Media

Regor Therapeutics Group - Company Profile

Regor Therapeutics Group, a China-based innovative drug discovery company, was founded in 2018. The company is dedicated to developing clinically differentiated medicines through its proprietary CARD (Computer Accelerated Rational Discovery) Platform, focusing on oncology, immunology, and metabolic disorders. Regor's approach integrates CARD with structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development, enabling the discovery of best- and first-in-class molecules. With a last investment of $50.00M from Eli Lilly in December 2021, Regor has established itself as a world-class player in the biotechnology and pharmaceutical industries.

Taxonomy: drug discovery, clinical stage company, innovative medicines, CARD Platform, oncology, immunology, metabolic disorders, proprietary technology, scientific team, new drug innovation, structural biology, computational chemistry, therapeutic biology, medicinal chemistry, clinical development

Funding Rounds & Investors of Regor Therapeutics Group (3)

View All
Funding Stage Amount No. Investors Investors Date
Venture Round $50.00M 1
Eli Lilly, investor in Regor Therapeutics Group's Venture Round round
10 Dec 2021
Series B $90.00M 5
Lilly Asia Ventures, investor in Regor Therapeutics Group's Series B round Vertex Ventures China, investor in Regor Therapeutics Group's Series B round Loyal Valley Capital, investor in Regor Therapeutics Group's Series B round TF Capital, investor in Regor Therapeutics Group's Series B round Lanting Capital, investor in Regor Therapeutics Group's Series B round
18 Feb 2021
Series A Unknown 1 Qilu Pharmaceutical 01 Jul 2018

Latest News of Regor Therapeutics Group

View All

No recent news or press coverage available for Regor Therapeutics Group.

Similar Companies to Regor Therapeutics Group

View All
Kalypsys - Similar company to Regor Therapeutics Group
Kalypsys Shaping the future of medicine through comprehensive, automated drug discovery and development services across multiple therapeutic areas.
Recursion - Similar company to Regor Therapeutics Group
Recursion Decoding Biology to Radically Improve Lives
Kojin Therapeutics - Similar company to Regor Therapeutics Group
Kojin Therapeutics Developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology
Genesis Drug Discovery & Development (GD³) - Similar company to Regor Therapeutics Group
Genesis Drug Discovery & Development (GD³) Our Science for Your Science
Nexo Therapeutics - Similar company to Regor Therapeutics Group
Nexo Therapeutics We are dedicated to the discovery and development of novel cancer therapies for patients with limited treatment options.
Circle Decoration Circle Decoration

Want to dive deeper into Regor Therapeutics Group? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now